1. Can you share your journey and how you became involved in the field of integrative oncology?

My journey into integrative oncology began with a personal experience that changed my perspective on cancer care. Watching a loved one navigate the difficult path of cancer treatment, I was profoundly affected by the stark challenges of conventional approaches and their impact on quality of life. This fuelled a passion in me to seek out and advocate for more holistic yet effective methods of supporting individuals battling cancer.

2. What inspired you to found Carer, and what are its key objectives in transforming cancer care?

The inspiration behind founding Carer stemmed from a deeply personal encounter with the limitations of conventional cancer treatment, witnessed through the experience of a loved one. This journey showcased the critical need for a more holistic approach to cancer care—one that not only targets the disease but also nurtures the overall well-being of the patient.

Carer was conceived with the vision to bridge this gap, offering comprehensive support that encompasses nutritional guidance, physical rehabilitation, mental health support, and financial counselling. Our key objectives are:

1. To enhance the quality of life for cancer patients, ensuring they receive care that addresses both their physical and emotional needs.
2. To improve treatment adherence and outcomes by integrating supportive care that complement traditional medical treatments.
3. To democratise access to integrative oncology services, making them available to patients across various socio-economic backgrounds and geographical locations.

Ultimately, Carer seeks to transform cancer care into a more patient-centric, holistic journey, ensuring that every individual facing this challenging path is supported, empowered, and cared for every step of the way.

3. How do you see personalised medicine impacting the future of cancer treatment?

Personalised medicine is set to revolutionise cancer treatment by focusing on tailored approaches that consider the unique genetic makeup of each patient. This patient-centric methodology not only promises better treatment outcomes but also a more holistic approach to healthcare. By integrating detailed genetic insights, treatments can be customised to target specific cancer cells, reducing side effects and improving efficacy.

Moreover, personalised medicine fosters a collaborative treatment process, actively involving patients and their families in decision-making. This inclusivity ensures that treatment plans resonate more deeply with the patient’s lifestyle, preferences, and concerns, enhancing adherence and satisfaction. In essence, personalised medicine heralds a future where cancer care is not just about battling the disease but about nurturing the patient’s overall well-being and dignity.

4. Can you discuss some cutting-edge technologies or therapies that are revolutionising cancer care?

Cancer care is witnessing a remarkable transformation thanks to cutting-edge technologies and therapies. Artificial Intelligence is at the forefront, improving diagnostic accuracy, predicting patient outcomes, and personalising treatment plans by analysing vast datasets. Precision medicine is another game-changer, tailoring treatments based on genetic, environmental, and lifestyle factors to maximise effectiveness and minimise side effects.

Furthermore, the exploration of the microbiome presents exciting possibilities. Research into how the body's microbial communities affect cancer progression and treatment response is leading to innovative therapeutic strategies, including microbiome modulation to enhance the efficacy of immunotherapies.

These advancements collectively represent a shift towards more personalized, effective, and patient-centred cancer care, promising improved outcomes and quality of life for patients.

5. What role do you believe artificial intelligence and machine learning will play in advancing cancer research and treatment?

Artificial intelligence and machine learning are set to play transformative roles in advancing cancer research and treatment. These technologies enhance our ability to analyse complex biological data, leading to breakthroughs in understanding cancer's mechanisms. In treatment, AI and ML are improving diagnostic precision, optimising treatment plans, and predicting patient outcomes with greater accuracy. They're also pivotal in drug discovery, significantly reducing the time and cost to bring new therapies to market. By integrating AI and ML into oncology, we're moving towards more personalised, effective, and efficient cancer care, promising a future where treatments are tailored to the individual needs and genetic profiles of patients.

6. What are the biggest challenges currently faced in cancer care, especially in the Asian healthcare landscape?

In the Asian healthcare landscape, several significant challenges are impacting cancer care delivery and outcomes. High treatment costs emerge as a paramount concern, making advanced therapies and drugs less accessible to a broad segment of the population. This financial burden often results in patients forgoing necessary treatments or exhausting their resources.

Lack of accessibility to high-quality care is another critical issue, especially in rural or underserved areas. There's a marked disparity in the availability of specialised cancer treatment facilities, which are predominantly located in urban centres, leaving those in remote regions with limited options.

Furthermore, integrative cancer care therapies, which encompass a holistic approach including nutritional, psychological, and physical support alongside conventional treatments, are yet to become mainstream within the region. Despite growing evidence supporting their benefits in improving patient outcomes and quality of life, these therapies are not widely adopted across Asian healthcare systems due to a lack of awareness and insufficient integration into standard care protocols.

Addressing these challenges requires concerted efforts across healthcare policy, insurance reform, and public awareness campaigns to improve affordability, access, and acceptance of comprehensive cancer care solutions.

7. How can healthcare systems address disparities in access to innovative cancer treatments, particularly in lower-income regions?

To address disparities in access to innovative cancer treatments in lower-income regions, healthcare systems can adopt a multi-faceted approach. First, implementing public-private partnerships can mobilise resources to subsidise the cost of cutting-edge treatments, making them more accessible to underserved populations. Additionally, investing in telehealth and mobile health initiatives can extend the reach of specialised care to remote areas, breaking down geographical barriers.

Healthcare systems can also focus on capacity building by training healthcare professionals in lower-income regions on the latest cancer care protocols, ensuring that patients everywhere have access to knowledgeable practitioners. Lastly, fostering collaborations between governments, NGOs, and pharmaceutical companies can lead to the development of affordable generic versions of expensive drugs, further enhancing accessibility.

By prioritising equity and innovation, healthcare systems can make significant strides toward ensuring that all patients, regardless of their economic status or location, have access to the cancer treatments they need.

8. Could you elaborate on the concept of integrative oncology and its benefits for cancer patients?

Integrative oncology is a patient-centred approach to cancer care that combines standard medical treatments like surgery, radiation, and chemotherapy with complementary therapies. These may include nutritional counselling, physical exercise, and mental health support aiming to support the patient's overall well-being, manage side effects, and enhance the efficacy of conventional treatments.

The benefits of integrative oncology for cancer patients are manifold. It addresses not just the physical aspects of the disease but also the emotional, social, and spiritual challenges that accompany a cancer diagnosis. By doing so, it can significantly improve patients' quality of life, reduce treatment side effects, increase treatment adherence and potentially enhance survival rates. Integrative oncology also empowers patients, giving them an active role in their care and recovery process, which can lead to improved satisfaction and outcomes. This holistic approach ensures that treatment plans are tailored to the individual needs of each patient, offering a more compassionate and comprehensive form of care.

9. What are your predictions for the future of cancer care, particularly in terms of new therapies or treatment modalities?

The future of cancer care is poised for transformative changes, driven by advancements in technology and a deeper understanding of cancer biology. Precision medicine will become increasingly central, tailoring treatments to the genetic profile of both the patient and the tumour, enhancing efficacy while minimising side effects. Immunotherapy, which harnesses the body’s immune system to fight cancer, is expected to evolve and combine with other treatments, offering more personalised and effective options.

Additionally, we'll see the rise of less invasive, targeted therapies that can accurately target tumour cells without harming surrounding tissues. The integration of artificial intelligence and machine learning in diagnostics and treatment planning will enable more accurate predictions of treatment outcomes, optimising therapeutic strategies.

Furthermore, the concept of integrative oncology, incorporating complementary therapies into conventional treatment plans, will gain mainstream acceptance, focusing on improving patients' quality of life and overall well-being. This holistic approach, alongside the rapid pace of scientific discovery, heralds a future where cancer care is more personalised, less invasive, and more focused on the patient as a whole.

10. How do you measure success and impact in your work, both personally and for Carer as an organisation?

Quantitatively we look at patient health outcomes, such as improvements in quality of life, increased treatment adherence rates, and overall survival rates. Metrics like patient enrolment numbers in our programmes and the scale of our reach, especially in underserved communities, also serve as key indicators of our impact.

Qualitatively patient and caregiver testimonials provide invaluable insights into the effectiveness and emotional impact of our services. The feedback from healthcare professionals about the integration and usefulness of our approach in their treatment plans is another crucial measure.

For me personally, success is also gauged by the ability to drive meaningful change in the oncology care ecosystem, fostering a more holistic, patient-centred approach in the broader healthcare community. It's about the stories of individuals who've regained hope and strength through our support.

Ultimately, for Carer, success means continuously pushing the boundaries of what's possible in cancer care, making a tangible difference in the lives of those we serve, and setting new standards for compassionate, comprehensive care.

--Issue 64--